{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:15:36Z","timestamp":1792613736623,"version":"4.5.0"},"reference-count":305,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Worldwide, nearly 40% of adults are overweight and 13% are obese. Health consequences of excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, and increased mortality. Treating obesity is challenging and calorie restriction often leads to rebound weight gain. Treatments such as bariatric surgery create hesitancy among patients due to their invasiveness. GLP-1 medications have revolutionized weight loss and can reduce body weight in obese patients by between 15% and 25% on average after about 1 year. Their mode of action is to mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism and satiety. However, GLP-1 drugs carry known risks and, since their use for weight loss is recent, may carry unforeseen risks as well. They carry a boxed warning for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) are fairly common while pancreatitis and intestinal obstruction are rarer. There may be a loss of lean body mass as well as premature facial aging. A significant disadvantage of using these medications is the high rate of weight regain when they are discontinued. Achieving success with pharmacologic treatment and then weaning to avoid future negative effects would be ideal.<\/jats:p>","DOI":"10.3390\/biom15030408","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:53:00Z","timestamp":1741848780000},"page":"408","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-2441","authenticated-orcid":false,"given":"Allison B.","family":"Reiss","sequence":"first","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"},{"name":"Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-0734","authenticated-orcid":false,"given":"Shelly","family":"Gulkarov","sequence":"additional","affiliation":[{"name":"Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-9673","authenticated-orcid":false,"given":"Stanislaw P.","family":"Klek","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-2183","authenticated-orcid":false,"given":"Ankita","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Renna","sequence":"additional","affiliation":[{"name":"Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"De Leon","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/oby.22378","article-title":"Obesity as a Disease: The Obesity Society 2018 Position Statement","volume":"27","author":"Jastreboff","year":"2019","journal-title":"Obesity"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1098\/rspb.1953.0009","article-title":"The role of depot fat in the hypothalamic control of food intake in the rat","volume":"140","author":"Kennedy","year":"1953","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1242\/dmm.008698","article-title":"Set points, settling points and some alternative models: Theoretical options to understand how genes and environments combine to regulate body adiposity","volume":"4","author":"Speakman","year":"2011","journal-title":"Dis. Models Mech."},{"key":"ref_4","first-page":"59","article-title":"Is there evidence for a set point that regulates human body weight?","volume":"2","author":"Heymsfield","year":"2010","journal-title":"F1000 Med. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-19-0399","article-title":"Mechanisms controlling hormone secretion in human gut and its relevance to metabolism","volume":"244","author":"Martin","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102848","DOI":"10.1016\/j.eclinm.2024.102848","article-title":"Burden of disease attributable to high body mass index: An analysis of data from the Global Burden of Disease Study 2021","volume":"76","author":"Zhou","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Choi, K.E., Joung, C., Pahk, K.J., Kim, H., and Pahk, K. (2024). Metabolic activity of visceral adipose tissue is associated with age-related macular degeneration: A pilot 18F-FDG PET\/CT study. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1322326"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kim, Y.H., Kim, S.M., Han, K.D., Jung, J.H., Lee, S.S., Oh, S.W., Park, H.S., Rhee, E.J., Lee, W.Y., and Yoo, S.J. (2019). Waist circumference and all-cause mortality independent of body mass index in korean population from the national health insurance health checkup 2009\u20132015. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010072"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/d41586-023-03143-x","article-title":"Why BMI is flawed\u2014And how to redefine obesity","volume":"622","author":"Prillaman","year":"2023","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/advances\/nmy055","article-title":"Humans against Obesity: Who Will Win?","volume":"10","author":"Caballero","year":"2019","journal-title":"Adv. Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40265-024-02029-0","article-title":"Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity","volume":"84","author":"Jude","year":"2024","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ward, Z.J., Bleich, S.N., Long, M.W., and Gortmaker, S.L. (2021). Association of body mass index with health care expenditures in the United States by age and sex. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247307"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/obr.12836","article-title":"A comprehensive diagnostic approach to detect underlying causes of obesity in adults","volume":"20","author":"Savas","year":"2019","journal-title":"Obes. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dell\u2019Olio, A., Scott, W.T., Taroncher-Ferrer, S., San Onofre, N., Soriano, J.M., and Rubert, J. (2024). Tailored impact of dietary fibers on gut microbiota: A multi-omics comparison on the lean and obese microbial communities. Microbiome, 12.","DOI":"10.1186\/s40168-024-01975-x"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41591-024-03299-7","article-title":"Subclassification of obesity for precision prediction of cardiometabolic diseases","volume":"31","author":"Coral","year":"2025","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41569-023-00847-5","article-title":"Obesity and the risk of cardiometabolic diseases","volume":"20","author":"Valenzuela","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/j.jacl.2024.04.001","article-title":"Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024","volume":"18","author":"Bays","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: Mechanisms and potential targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/mmr.2024.13219","article-title":"Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation-mediating treatment options (Review)","volume":"29","author":"Varra","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity Phenotypes, Diabetes, and Cardiovascular Diseases","volume":"126","author":"Tchernof","year":"2020","journal-title":"Circ. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"de Lima, E.P., Moretti, R.C., Torres Pomini, K., Laurindo, L.F., Sloan, K.P., Sloan, L.A., Castro, M.V.M., Baldi, E., Ferraz, B.F.R., and de Souza Bastos Mazuqueli Pereira, E. (2024). Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways. Biology, 13.","DOI":"10.3390\/biology13070519"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kajikawa, M., and Higashi, Y. (2022). Obesity and Endothelial Function. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071745"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"loae029","DOI":"10.1093\/lifemeta\/loae029","article-title":"Potential therapeutic strategies for MASH: From preclinical to clinical development","volume":"3","author":"Xie","year":"2024","journal-title":"Life Metab."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Alp\u00edzar Salazar, M., Olgu\u00edn Reyes, S.E., Medina Est\u00e9vez, A., Saturno Lobos, J.A., De Aldecoa Castillo, J.M., Carrera Aguas, J.C., Alaniz Monreal, S., Navarro Rodr\u00edguez, J.A., and Alp\u00edzar S\u00e1nchez, D.M.F. (2025). Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma. Medicina, 61.","DOI":"10.3390\/medicina61010088"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kaya, E., Syn, W.K., and Manka, P. (2025). Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: Hitting two targets with one shot. Curr. Opin. Gastroenterol., advance online publication.","DOI":"10.1097\/MOG.0000000000001083"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ghnaim, A., Midlej, K., Zohud, O., Karram, S., Schaefer, A., Houri-Haddad, Y., Lone, I.M., and Iraqi, F.A. (2024). Host Genetics Background Affects Intestinal Cancer Development Associated with High-Fat Diet-Induced Obesity and Type 2 Diabetes. Cells, 13.","DOI":"10.20944\/preprints202409.1094.v1"},{"key":"ref_29","first-page":"656","article-title":"Esophageal cancer global burden profiles, trends, and contributors","volume":"21","author":"Teng","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.21037\/tcr-24-744","article-title":"Research progress on the correlation between obesity and the occurrence and development of kidney cancer: A narrative review","volume":"13","author":"Kang","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41416-024-02857-7","article-title":"Association of metabolic obesity phenotypes with risk of overall and site-specific cancers: A systematic review and meta-analysis of cohort studies","volume":"131","author":"Aune","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Solsona-Vilarrasa, E., and Vousden, K.H. (2024). Obesity, white adipose tissue and cancer. FEBS J., advance online publication.","DOI":"10.1111\/febs.17312"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Borges, M., Sampaio, F., Costa, J., Freitas, P., Matias Dias, C., Gaio, V., Conde, V., Figueira, D., Pinheiro, B., and Silva Miguel, L. (2024). Burden of disease and cost of illness of overweight and obesity in Portugal. Obes. Facts, advance online publication.","DOI":"10.1159\/000541781"},{"key":"ref_34","first-page":"378","article-title":"Obesity: A Profoundly Under Recognized Chronic Disease, And Its Impacts on Cardiovascular Disease","volume":"77","author":"Asif","year":"2024","journal-title":"South Dak. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhang, M., Weng, X., Xu, J., and Xu, X. (2024). Correlation between obstructive sleep apnea and weight-adjusted-waist index: A cross-sectional study. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1463184"},{"key":"ref_36","first-page":"00019","article-title":"Obstructive Sleep Apnea and Obesity: Implications for Public Health","volume":"1","author":"Jehan","year":"2017","journal-title":"Sleep Med. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11325-017-1599-x","article-title":"Relationships between MRI fat distributions and sleep apnea and obesity hypoventilation syndrome in very obese patients","volume":"22","author":"Turnbull","year":"2018","journal-title":"Sleep Breath."},{"key":"ref_38","first-page":"e30535","article-title":"Chronic Kidney Disease: Its Relationship With Obesity","volume":"14","author":"Prasad","year":"2022","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/singaporemedj.SMJ-2022-232","article-title":"The impact of obesity: A narrative review","volume":"64","author":"Lam","year":"2023","journal-title":"Singap. Med. J."},{"key":"ref_40","first-page":"5917","article-title":"Shared biological mechanisms of depression and obesity: Focus on adipokines and lipokines","volume":"15","author":"Fu","year":"2023","journal-title":"Aging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.mcna.2022.03.002","article-title":"Medical and Surgical Treatment of Obesity","volume":"106","author":"Reid","year":"2022","journal-title":"Med. Clin. N. Am."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tric\u00f2, D., Moriconi, D., Berta, R., Baldi, S., Quinones-Galvan, A., Guiducci, L., Taddei, S., Mari, A., and Nannipieri, M. (2021). Effects of Low-Carbohydrate versus Mediterranean Diets on Weight Loss, Glucose Metabolism, Insulin Kinetics and \u03b2-Cell Function in Morbidly Obese Individuals. Nutrients, 13.","DOI":"10.3390\/nu13041345"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clnesp.2024.08.023","article-title":"Comparison of weight loss effects among overweight\/obese adults: A network meta-analysis of mediterranean, low carbohydrate, and low-fat diets","volume":"64","author":"Akbari","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/jama.2018.0245","article-title":"Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial","volume":"319","author":"Gardner","year":"2018","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa0804748","article-title":"Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates","volume":"360","author":"Sacks","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.293.1.43","article-title":"Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial","volume":"293","author":"Dansinger","year":"2005","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1161\/CIR.0000000000001146","article-title":"Popular Dietary Patterns: Alignment With American Heart Association 2021 Dietary Guidance: A Scientific Statement From the American Heart Association","volume":"147","author":"Anderson","year":"2023","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S2213-8587(15)00367-8","article-title":"Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: A systematic review and meta-analysis","volume":"3","author":"Tobias","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1210\/jc.2002-021480","article-title":"A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women","volume":"88","author":"Brehm","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101109","DOI":"10.1016\/j.jacadv.2024.101109","article-title":"Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis: The KETO Trial","volume":"3","author":"Budoff","year":"2024","journal-title":"JACC Adv."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kripp, A.M., Feichter, A., and K\u00f6nig, D. (2024). A low-carbohydrate, high-fat diet leads to unfavorable changes in blood lipid profiles compared to carbohydrate-rich diets with different glycemic indices in recreationally active men. Front. Nutr., 11.","DOI":"10.3389\/fnut.2024.1473747"},{"key":"ref_52","first-page":"CD013334","article-title":"Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk","volume":"1","author":"Naude","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Chawla, S., Tessarolo Silva, F., Amaral Medeiros, S., Mekary, R.A., and Radenkovic, D. (2020). The Effect of Low-Fat and Low-Carbohydrate Diets on Weight Loss and Lipid Levels: A Systematic Review and Meta-Analysis. Nutrients, 12.","DOI":"10.3390\/nu12123774"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1249\/MSS.0000000000003520","article-title":"Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus Statement","volume":"56","author":"Jakicic","year":"2024","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/09637486.2017.1417978","article-title":"The Mediterranean Diet: Its definition and evaluation of a priori dietary indexes in primary cardiovascular prevention","volume":"69","year":"2018","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/joim.13333","article-title":"The Mediterranean diet and health: A comprehensive overview","volume":"290","author":"Willett","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_57","unstructured":"(2025, January 03). Best Diets Overall 2025. Available online: https:\/\/health.usnews.com\/best-diet\/best-diets-overall."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Green, M., Arora, K., and Prakash, S. (2020). Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082890"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e70012","DOI":"10.1002\/mco2.70012","article-title":"Gut microbiota in health and disease: Advances and future prospects","volume":"5","author":"Zhang","year":"2024","journal-title":"MedComm"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"806896","DOI":"10.1155\/2011\/806896","article-title":"Taking Orlistat: Predicting weight loss over 6 months","volume":"2011","author":"Hollywood","year":"2011","journal-title":"J. Obes."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/2230-8210.81938","article-title":"Evaluation of efficacy and safety of orlistat in obese patients","volume":"15","author":"Jain","year":"2011","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group","volume":"8","author":"Noack","year":"2000","journal-title":"Obes. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14740338.2017.1247807","article-title":"Safety assessment of combination therapies in the treatment of obesity: Focus on naltrexone\/bupropion extended release and phentermine-topiramate extended release","volume":"16","author":"Halpern","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of Naltrexone plus Bupropion on Weight Loss in Overweight and Obese Adults (COR-I): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"ref_65","first-page":"164","article-title":"Naltrexone\/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults","volume":"41","author":"Sherman","year":"2016","journal-title":"Pharm. Ther."},{"key":"ref_66","first-page":"446","article-title":"Phentermine\/Topiramate extended-release capsules (qsymia) for weight loss","volume":"38","author":"Lonneman","year":"2013","journal-title":"Pharm. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/13645706.2021.1874420","article-title":"Intragastric balloon","volume":"31","author":"Silva","year":"2022","journal-title":"Minim. Invasive Ther. Allied Technol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41366-024-01678-1","article-title":"Endoscopic bariatric surgery for adults with overweight and obesity: A systematic review and network meta-analysis","volume":"49","author":"Zhu","year":"2024","journal-title":"Int. J. Obes."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.suc.2024.06.012","article-title":"Current State of Endoscopic Bariatric Therapies","volume":"105","author":"Ying","year":"2025","journal-title":"Surg. Clin. N. Am."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wyszomirski, K., Wal\u0119dziak, M., and R\u00f3\u017ca\u0144ska-Wal\u0119dziak, A. (2023). Obesity, Bariatric Surgery and Obstructive Sleep Apnea-A Narrative Literature Review. Medicina, 59.","DOI":"10.3390\/medicina59071266"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/SLA.0000000000004174","article-title":"Banded Versus Nonbanded Sleeve Gastrectomy: A Randomized Controlled Trial With 3 Years of Follow-up","volume":"272","author":"Fink","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_73","first-page":"e72961","article-title":"Long-Term Outcomes of Sleeve Gastrectomy Versus Gastric Bypass","volume":"16","author":"Alaidaroos","year":"2024","journal-title":"Cureus"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"116242","DOI":"10.1016\/j.amjsurg.2025.116242","article-title":"Metabolic and bariatric surgery versus glucagon-like peptide-1 receptor agonist therapy: A comparison of cardiovascular outcomes in patients with obesity","volume":"242","author":"Maan","year":"2025","journal-title":"Am. J. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11695-024-07578-7","article-title":"A Longer Biliopancreatic Limb and Shorter Common Channel Enhance Weight Loss But May Have Harmful Effects in Mouse Models of Roux-en-Y Gastric Bypass","volume":"35","author":"Lau","year":"2025","journal-title":"Obes. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajem.2024.10.050","article-title":"High risk and low incidence diseases: Bariatric surgery complications","volume":"87","author":"Farooqi","year":"2025","journal-title":"Am. J. Emerg. Med."},{"key":"ref_77","first-page":"e71919","article-title":"Real-Time Perfusion and Leak Assessment in Bariatric Surgery: Bridging Traditional and Advanced Techniques","volume":"16","author":"Farah","year":"2024","journal-title":"Cureus"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and Risks of Bariatric Surgery in Adults: A Review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e000219","DOI":"10.1136\/tsaco-2018-000219","article-title":"Early and late complications of bariatric operation","volume":"3","author":"Lim","year":"2018","journal-title":"Trauma Surg. Acute Care Open"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"\u00c7al\u0131k Ba\u015faran, N., Dotan, I., and Dicker, D. (2025). Post metabolic bariatric surgery weight regain: The importance of GLP-1 levels. Int. J. Obes., advance online publication.","DOI":"10.1038\/s41366-024-01461-2"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.orcp.2025.02.004","article-title":"Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition","volume":"19","author":"Stoll","year":"2025","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: A Retrospective Observational Study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes. Surg."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMcibr2409089","article-title":"Discovery of GLP-1-Based Drugs for the Treatment of Obesity","volume":"392","author":"Drucker","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e2457232","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal Analysis of Obesity Drug Use and Public Awareness","volume":"8","author":"Berning","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1053\/j.gastro.2017.01.052","article-title":"Obesity Energetics: Body Weight Regulation and the Effects of Diet Composition","volume":"152","author":"Hall","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Petrovic, A., Jovicic, S., Dodevska, M., Djordjevic, B., Milinkovic, N., and Ivanovic, N.D. (2024). Effects of Specially Designed Energy-Restricted Diet on Anthropometric Parameters and Cardiometabolic Risk in Overweight and Obese Adults: Pilot Study. Nutrients, 16.","DOI":"10.3390\/nu16203453"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2015.04.004","article-title":"The genetics of lipid storage and human lipodystrophies","volume":"21","author":"Robbins","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"De Fano, M., Malara, M., Vermigli, C., and Murdolo, G. (2024). Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168650"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/lifemeta\/loac002","article-title":"Obesity: An evolutionary context","volume":"1","author":"Speakman","year":"2022","journal-title":"Life Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gut.38.6.916","article-title":"Attenuated GLP-1 secretion in obesity: Cause or consequence?","volume":"38","author":"Ranganath","year":"1996","journal-title":"Gut"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2337\/db14-1751","article-title":"Glucagon-like peptide-1 (GLP-1) response to oral glucose is reduced in pre-diabetes, screen-detected type 2 diabetes and obesity, and influenced by sex: The ADDITION-PRO study","volume":"64","author":"Faerch","year":"2015","journal-title":"Diabetes"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrendo.2011.77","article-title":"GLP-1 and energy balance: An integrated model of short-term and long-term control","volume":"7","author":"Barrera","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/db14-0302","article-title":"GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK","volume":"63","author":"Beiroa","year":"2014","journal-title":"Diabetes"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/db11-1556","article-title":"Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling","volume":"61","author":"Lockie","year":"2012","journal-title":"Diabetes"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"154167","DOI":"10.1016\/j.metabol.2020.154167","article-title":"Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males","volume":"106","author":"Janssen","year":"2020","journal-title":"Metabolism"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"Sloth","year":"2014","journal-title":"Int. J. Obes."},{"key":"ref_102","first-page":"T1","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS","volume":"221","author":"Ijzerman","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/met.2018.0088","article-title":"The Role of Glucagon-Like Peptide-1 in Energy Homeostasis","volume":"17","author":"Salehi","year":"2019","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Kleinert, M., Sachs, S., Habegger, K.M., Hofmann, S.M., and M\u00fcller, T.D. (2019). Glucagon Regulation of Energy Expenditure. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215407"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/oby.23374","article-title":"Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss","volume":"30","author":"Christoffersen","year":"2022","journal-title":"Obesity"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bph.15638","article-title":"Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment","volume":"179","author":"Trapp","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1523\/JNEUROSCI.3262-11.2011","article-title":"Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake","volume":"31","author":"Dossat","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1210\/en.2014-1248","article-title":"GLP-1 receptor stimulation of the lateral parabrachial nucleus reduces food intake: Neuroanatomical, electrophysiological, and behavioral evidence","volume":"155","author":"Richard","year":"2014","journal-title":"Endocrinology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbrc.2014.07.116","article-title":"Endogenous GLP-1 acts on paraventricular nucleus to suppress feeding: Projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin-1 and oxytocin neurons","volume":"451","author":"Katsurada","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Zeng, Y., Wu, Y., Zhang, Q., and Xiao, X. (2024). Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases. mBio, 15.","DOI":"10.1128\/mbio.02032-23"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cmet.2019.08.009","article-title":"Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice","volume":"30","author":"Song","year":"2019","journal-title":"Cell Metab."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.pneurobio.2010.07.003","article-title":"Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides","volume":"92","author":"Vrang","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2174\/1381612033454775","article-title":"Central pre-proglucagon derived peptides: Opportunities for treatment of obesity","volume":"9","author":"Larsen","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","article-title":"Central and peripheral GLP-1 systems independently suppress eating","volume":"3","author":"Brierley","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"11811","DOI":"10.1039\/D4FO04024D","article-title":"Bioactive compounds regulate appetite through the melanocortin system: A review","volume":"15","author":"Niu","year":"2024","journal-title":"Food Funct."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-18-0596","article-title":"The melanocortin pathway and control of appetite-progress and therapeutic implications","volume":"241","author":"Baldini","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cmet.2011.02.001","article-title":"Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation","volume":"13","author":"Hayes","year":"2011","journal-title":"Cell Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1523\/JNEUROSCI.3579-15.2016","article-title":"Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance","volume":"36","author":"Reiner","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Masaki, T., Ozeki, Y., Yoshida, Y., Okamoto, M., Miyamoto, S., Gotoh, K., and Shibata, H. (2022). Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients. Metabolites, 12.","DOI":"10.3390\/metabo12020147"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/eurheartj\/ehae028","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: The SUSTAIN 6 and PIONEER 6 trials","volume":"45","author":"Mellbin","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_123","first-page":"4020492","article-title":"GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes","volume":"2018","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: A meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2024.11.008","article-title":"Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity","volume":"85","author":"Verma","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., and Yang, J. (2024). Anti-atherosclerotic effect of incretin receptor agonists. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1463547"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Lin, Y.M., Wu, J.Y., Lee, M.C., Su, C.L., Toh, H.S., Chang, W.T., Chen, S.Y., Kuo, F.H., Tang, H.J., and Liao, C.T. (2025). Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: A systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother., advance online publication.","DOI":"10.1093\/ehjcvp\/pvae093"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40001-024-02241-4","article-title":"Comparative efficacy of GLP-1 RAs\/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int. J. Obes."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the asia-pacific region: The SURPASS-AP-combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41366-023-01337-x","article-title":"Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: A meta-analysis of randomized controlled trials","volume":"47","author":"Padrao","year":"2023","journal-title":"Int. J. Obes."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Jastreboff","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.obpill.2024.100122","article-title":"Frequently asked questions to the 2023 obesity medicine association position statement on compounded peptides: A call for action","volume":"11","author":"Bays","year":"2024","journal-title":"Obes. Pillars"},{"key":"ref_140","first-page":"789","article-title":"Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines","volume":"42","author":"Hung","year":"2002","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13181-020-00814-3","article-title":"Pharmaceutical Compounding: A History, Regulatory Overview, and Systematic Review of Compounding Errors","volume":"17","author":"Watson","year":"2021","journal-title":"J. Med. Toxicol."},{"key":"ref_142","unstructured":"(2024, November 27). DA Warns Consumers Not to Use Counterfeit Ozempic (Semaglutide) Found in U.S. Drug Supply Chain, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K","article-title":"Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes","volume":"20","year":"1998","journal-title":"Bioessays"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Popoviciu, M.S., P\u0103duraru, L., Yahya, G., Metwally, K., and Cavalu, S. (2023). Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310449"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/dom.14171","article-title":"Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?","volume":"22","author":"Graham","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/bcpt.13169","article-title":"Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant","volume":"124","author":"Yap","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int. J. Obes."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial","volume":"389","author":"Astrup","year":"2017","journal-title":"Lancet"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1507\/endocrj.EJ24-0286","article-title":"A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database","volume":"72","author":"Li","year":"2024","journal-title":"Endocr. J."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Gorgojo-Mart\u00ednez, J.J., Mezquita-Raya, P., Carretero-G\u00f3mez, J., Castro, A., Cebri\u00e1n-Cuenca, A., de Torres-S\u00e1nchez, A., Garc\u00eda-de-Lucas, M.D., N\u00fa\u00f1ez, J., Obaya, J.C., and Soler, M.J. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010145"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-024-07685-6","article-title":"Dissociable hindbrain GLP1R circuits for satiety and aversion","volume":"632","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obes. Pillars"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1089\/dia.2013.0274","article-title":"Incretin-based therapies: Facing the realities of benefits versus side effects","volume":"15","author":"Lebovitz","year":"2013","journal-title":"Diabetes Technol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"100162","DOI":"10.1016\/j.obpill.2025.100162","article-title":"Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials","volume":"13","author":"Guo","year":"2025","journal-title":"Obes. Pillars"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr. Pract."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7570\/jomes20059","article-title":"Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes","volume":"30","author":"Seo","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_163","unstructured":"(2024, December 05). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf."},{"key":"ref_164","first-page":"G984","article-title":"Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow","volume":"275","author":"Wettergren","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","article-title":"Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: Data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/00185787221125724","article-title":"Tirzepatide","volume":"58","author":"Baker","year":"2023","journal-title":"Hosp. Pharm."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Alenzi, K.A., Alsuhaibani, D., Batarfi, B., and Alshammari, T.M. (2024). Pancreatitis with use of new diabetic medications: A real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1364110"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/jdi.14229","article-title":"A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data","volume":"15","author":"Du","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00019","article-title":"Short-term medical benefits and adverse effects of weight loss","volume":"119","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes. Rev."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Kim, H.J., Kang, T.U., Kim, M.J., Swan, H., and Park, S.M. (2024). Long-term weight patterns and physical activity in gallstones. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-77218-8"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/jdv.17079","article-title":"Common causes of hair loss\u2014Clinical manifestations, trichoscopy and therapy","volume":"35","author":"Alessandrini","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ijd.17246","article-title":"GLP-1 agonists and hair loss: A call for further investigation","volume":"63","author":"Desai","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/PPA.S419304","article-title":"The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects","volume":"18","author":"Jensen","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1002\/osp4.756","article-title":"Healthcare professionals\u2019 perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists","volume":"10","author":"Garvey","year":"2024","journal-title":"Obes. Sci. Pract."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/a-2148-6321","article-title":"Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons","volume":"39","author":"Humphrey","year":"2023","journal-title":"Facial Plast. Surg."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bjps.2024.07.051","article-title":"The rise of \u201cOzempic Face\u201d: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists","volume":"96","author":"Mansour","year":"2024","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"bvae164","DOI":"10.1210\/jendso\/bvae164","article-title":"Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments","volume":"8","author":"Tinsley","year":"2024","journal-title":"J. Endocr. Soc."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: Insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., Itani, L., and El Ghoch, M. (2024). The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies. Diseases, 12.","DOI":"10.3390\/diseases12090204"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.orcp.2025.01.009","article-title":"Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review","volume":"19","author":"Schmidt","year":"2025","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"156113","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","article-title":"Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node","volume":"120","author":"Lubberding","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Wei, J., Wang, R., Ye, H., Wang, Y., Wang, L., and Zhang, X. (2022). Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.910256"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/00015385.2022.2087839","article-title":"Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias","volume":"78","author":"Boulmpou","year":"2023","journal-title":"Acta Cardiol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.21037\/atm-21-4162","article-title":"Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: A real-world analysis of post-marketing surveillance data","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.14336\/AD.2019.0303","article-title":"Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","volume":"10","author":"Gao","year":"2019","journal-title":"Aging Dis."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Xie, Y., Choi, T., and Al-Aly, Z. (2025). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med., advance online publication.","DOI":"10.1038\/s41591-024-03412-w"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Zhou, J., Huang, W., Xie, Y., Shen, H., Liu, M., and Wu, X. (2024). Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: A pharmacovigilance study based on the FDA adverse event reporting system database. Endocrine, advance online publication.","DOI":"10.1007\/s12020-024-04112-8"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"108255","DOI":"10.1016\/j.jdiacomp.2022.108255","article-title":"Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes\u2014A systematic review and meta-analysis","volume":"36","author":"Yoshida","year":"2022","journal-title":"J. Diabetes Complicat."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study","volume":"265","author":"Wai","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"ref_198","first-page":"11","article-title":"Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?","volume":"72","author":"Singh","year":"2024","journal-title":"J. Assoc. Physicians India"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide\u2014The FDA\u2019s review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 Receptor Agonists and the Risk of Thyroid Cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e078225","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","article-title":"Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases","volume":"47","author":"Wang","year":"2022","journal-title":"Endocr. Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: A review","volume":"232","author":"Drummond","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e12690","DOI":"10.1111\/cob.12690","article-title":"What is known about the use of weight loss medication in women with overweight\/obesity on fertility and reproductive health outcomes? A scoping review","volume":"14","author":"Maslin","year":"2024","journal-title":"Clin. Obes."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Pavli, P., Triantafyllidou, O., Kapantais, E., Vlahos, N.F., and Valsamakis, G. (2024). Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031909"},{"key":"ref_208","first-page":"20","article-title":"Preliminary Review Finds No Link Between GLP-1 Receptor Agonists and Suicidality","volume":"124","author":"Aschenbrenner","year":"2024","journal-title":"Am. J. Nurs."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 Receptor Agonist Use and Risk of Suicide Death","volume":"184","author":"Ueda","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"103758","DOI":"10.1016\/j.numecd.2024.09.028","article-title":"Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: A real-world study from FAERS","volume":"35","author":"Tian","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae)","volume":"369","author":"McIntyre","year":"2025","journal-title":"J. Affect. Disord."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamapediatrics.2024.3812","article-title":"Risk of Suicidal Ideation or Attempts in Adolescents With Obesity Treated With GLP1 Receptor Agonists","volume":"178","author":"Kerem","year":"2024","journal-title":"JAMA Pediatr."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e23.00506","DOI":"10.2106\/JBJS.CC.23.00506","article-title":"Retained Gastric Contents After Adequate Fasting Associated with GLP-1 Receptor Agonist Use: A Report of 3 Cases","volume":"13","author":"Kittner","year":"2023","journal-title":"JBJS Case Connect."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Goron, A.R., Connolly, C., Valdez-Sinon, A.N., Hesson, A., Helou, C., and Kirschen, G.W. (2024). Anti-Hyperglycemic Medication Management in the Perioperative Setting: A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist. J. Clin. Med., 13.","DOI":"10.3390\/jcm13206259"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.soard.2024.08.033","article-title":"Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period","volume":"20","author":"Kindel","year":"2024","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"111668","DOI":"10.1016\/j.jclinane.2024.111668","article-title":"Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study","volume":"99","author":"Santos","year":"2024","journal-title":"J. Clin. Anesth."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0566","article-title":"Glucagon-Like Peptide-1 Receptor Agonists in the Peri-Operative Period","volume":"86","author":"Narasimhan","year":"2025","journal-title":"Br. J. Hosp. Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/87551225221092681","article-title":"Once-Weekly Semaglutide for Weight Management: A Clinical Review","volume":"38","author":"Fornes","year":"2022","journal-title":"J. Pharm. Technol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","article-title":"GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?","volume":"24","author":"Pedrosa","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"bqae167","DOI":"10.1210\/endocr\/bqae167","article-title":"GLP-1 and the Neurobiology of Eating Control: Recent Advances","volume":"166","author":"Jones","year":"2025","journal-title":"Endocrinology"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eprac.2023.12.010","article-title":"A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management","volume":"30","author":"Chetty","year":"2024","journal-title":"Endocr. Pract."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"102475","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/oby.21538","article-title":"Persistent metabolic adaptation 6 years after \u201cThe Biggest Loser\u201d competition","volume":"24","author":"Fothergill","year":"2016","journal-title":"Obesity"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"R581","DOI":"10.1152\/ajpregu.00755.2010","article-title":"Biology\u2019s response to dieting: The impetus for weight regain","volume":"301","author":"Maclean","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Falkenhain, K., Martin, C.K., Ravussin, E., and Redman, L.M. (2024). Energy expenditure, metabolic adaptation, physical activity and energy intake following weight loss: Comparison between bariatric surgery and low-calorie diet. Eur. J. Clin. Nutr., advance online publication.","DOI":"10.1038\/s41430-024-01523-8"},{"key":"ref_226","first-page":"F1000","article-title":"Recent advances in understanding body weight homeostasis in humans","volume":"7","author":"Geisler","year":"2018","journal-title":"F1000Research"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cmet.2008.12.006","article-title":"Models use leptin and calculus to count calories","volume":"9","author":"Hall","year":"2009","journal-title":"Cell Metab."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eprac.2021.11.082","article-title":"Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications","volume":"28","author":"Garvey","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mcna.2017.08.012","article-title":"Maintenance of Lost Weight and Long-Term Management of Obesity","volume":"102","author":"Hall","year":"2018","journal-title":"Med. Clin. N. Am."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s42255-023-00864-1","article-title":"Differential mechanisms affecting weight loss and weight loss maintenance","volume":"5","author":"Rosenbaum","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/ajcn\/nqac031","article-title":"The energy balance model of obesity: Beyond calories in, calories out","volume":"115","author":"Hall","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1519\/JSC.0000000000003991","article-title":"Metabolic Adaptations to Weight Loss: A Brief Review","volume":"36","author":"Roberts","year":"2022","journal-title":"J. Strength Cond. Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/ajcn\/nqy179","article-title":"No consistent evidence of a disproportionately low resting energy expenditure in long-term successful weight-loss maintainers","volume":"108","author":"Ostendorf","year":"2018","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1111\/dom.15802","article-title":"Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial","volume":"26","author":"Gabe","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/oby.21653","article-title":"How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake","volume":"24","author":"Polidori","year":"2016","journal-title":"Obesity"},{"key":"ref_236","first-page":"2563","article-title":"Metabolic adaptation following massive weight loss is related to the degree of energy imbalance and changes in circulating leptin","volume":"22","author":"Knuth","year":"2014","journal-title":"Obesity"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"E1512","DOI":"10.1210\/jc.2011-1286","article-title":"The fall in leptin concentration is a major determinant of the metabolic adaptation induced by caloric restriction independently of the changes in leptin circadian rhythms","volume":"96","author":"Lecoultre","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"149225","DOI":"10.1016\/j.brainres.2024.149225","article-title":"Principal components analysis on genes related to inflammasome complex and microglial activation in the hypothalamus of obese mice treated with semaglutide (GLP-1 analog)","volume":"1846","author":"Marinho","year":"2024","journal-title":"Brain Res."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2022.06.002","article-title":"Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions","volume":"34","author":"Imbernon","year":"2022","journal-title":"Cell Metab."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"995","DOI":"10.7326\/M23-0744","article-title":"Hunger and the Obesity Epidemic: Old Insights Reaffirmed by New Medicines?","volume":"176","author":"Taylor","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amepre.2013.08.019","article-title":"Weight-loss maintenance for 10 years in the National Weight Control Registry","volume":"46","author":"Thomas","year":"2014","journal-title":"Am. J. Prev. Med."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/osp4.22","article-title":"Internal disinhibition predicts 5-year weight regain in the National Weight Control Registry (NWCR)","volume":"2","author":"Lillis","year":"2016","journal-title":"Obes. Sci. Pract."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"e13003","DOI":"10.1111\/obr.13003","article-title":"Successful weight loss maintenance: A systematic review of weight control registries","volume":"21","author":"Dias","year":"2020","journal-title":"Obes. Rev."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/ncp.10885","article-title":"The consequences of a weight-centric approach to healthcare: A case for a paradigm shift in how clinicians address body weight","volume":"37","author":"Mauldin","year":"2022","journal-title":"Nutr. Clin. Pract."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/oby.23905","article-title":"New insights in the mechanisms of weight-loss maintenance: Summary from a Pennington symposium","volume":"31","author":"Flanagan","year":"2023","journal-title":"Obesity"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa2114833","article-title":"Calorie Restriction with or without Time-Restricted Eating in Weight Loss","volume":"386","author":"Liu","year":"2022","journal-title":"N. Eng. J. Med."},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Minderis, P., Fokin, A., Povilonis, T., Kvedaras, M., and Ratkevicius, A. (2023). Effects of Diet Macronutrient Composition on Weight Loss during Caloric Restriction and Subsequent Weight Regain during Refeeding in Aging Mice. Nutrients, 15.","DOI":"10.3390\/nu15224836"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"e13398","DOI":"10.1111\/obr.13398","article-title":"How does the food environment influence people engaged in weight management? A systematic review and thematic synthesis of the qualitative literature","volume":"23","author":"Neve","year":"2022","journal-title":"Obes. Rev."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1016\/j.clnu.2021.08.009","article-title":"Consumption of ultra-processed foods associated with weight gain and obesity in adults: A multi-national cohort study","volume":"40","author":"Cordova","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.physbeh.2018.01.025","article-title":"Is regular exercise an effective strategy for weight loss maintenance?","volume":"188","author":"Foright","year":"2018","journal-title":"Phys. Behav."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.cub.2015.12.046","article-title":"Constrained Total Energy Expenditure and Metabolic Adaptation to Physical Activity in Adult Humans","volume":"26","author":"Pontzer","year":"2016","journal-title":"Curr. Biol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pcad.2018.07.014","article-title":"The Effects of Exercise and Physical Activity on Weight Loss and Maintenance","volume":"61","author":"Swift","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/archinte.168.14.1550","article-title":"Effect of exercise on 24-month weight loss maintenance in overweight women","volume":"168","author":"Jakicic","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jama.290.10.1323","article-title":"Effect of exercise duration and intensity on weight loss in overweight sedentary women","volume":"290","author":"Jakicic","year":"2003","journal-title":"JAMA"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/ds17-0013","article-title":"Role of Physical Activity for Weight Loss and Weight Maintenance","volume":"30","author":"Cox","year":"2017","journal-title":"Diabetes Spectr."},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"Ghoreishy, S.M., Noormohammadi, M., Zeraattalab-Motlagh, S., Shoaibinobarian, N., Hasan Rashedi, M., Movahed, S., Hemmati, A., Nazarian, A., Fernandez, M.L., and Shidfar, F. (2024). The Effectiveness of Nonsurgical Interventions for Weight Loss Maintenance in Adults: An Updated, GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutr. Rev., nuae128. advance online publication.","DOI":"10.1093\/nutrit\/nuae128"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/osp4.530","article-title":"Predictors of long-term weight loss trajectories during a behavioral weight loss intervention: An exploratory analysis","volume":"7","author":"Ostendorf","year":"2021","journal-title":"Obes. Sci. Pract."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/oby.22052","article-title":"Objectively Measured Physical Activity and Sedentary Behavior in Successful Weight Loss Maintainers","volume":"26","author":"Ostendorf","year":"2018","journal-title":"Obesity"},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"McCarthy, D., and Berg, A. (2021). Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss. Nutrients, 13.","DOI":"10.3390\/nu13072473"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s12671-022-01951-2","article-title":"Effects of a Mindfulness-Based Weight Loss Intervention on Long-Term Psychological Well-Being Among Adults with Obesity: Secondary Analyses from the Supporting Health by Integrating Nutrition and Exercise (SHINE) Trial","volume":"13","author":"Hooker","year":"2022","journal-title":"Mindfulness"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/obr.12052","article-title":"A systematic review of variables associated with the relationship between obesity and depression","volume":"14","author":"Preiss","year":"2013","journal-title":"Obes. Rev."},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Jackson, S.E., Steptoe, A., Beeken, R.J., Kivimaki, M., and Wardle, J. (2014). Psychological changes following weight loss in overweight and obese adults: A prospective cohort study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104552"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1037\/a0014159","article-title":"Maintaining large weight losses: The role of behavioral and psychological factors","volume":"76","author":"Wing","year":"2008","journal-title":"J. Consult. Clin. Psychol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"e12580","DOI":"10.1111\/cob.12580","article-title":"Psychological support within tier 2 adult weight management services, are we doing enough for people with mental health needs? A mixed-methods survey","volume":"13","author":"Marwood","year":"2023","journal-title":"Clin. Obes."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1007\/s11695-020-05164-1","article-title":"Multidisciplinary Approach for Weight Regain-how to Manage this Challenging Condition: An Expert Review","volume":"31","author":"Cambi","year":"2021","journal-title":"Obes. Surg."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10865-016-9717-y","article-title":"The role of social support in weight loss maintenance: Results from the MedWeight study","volume":"39","author":"Karfopoulou","year":"2016","journal-title":"J. Behav. Med."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jand.2011.11.014","article-title":"Similarities and differences between weight loss maintainers and regainers: A qualitative analysis","volume":"112","author":"Reyes","year":"2012","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5993\/AJHB.42.1.8","article-title":"Long-term Weight Maintenance after Successful Weight Loss: Motivational Factors, Support, Difficulties, and Success Factors","volume":"42","author":"Soini","year":"2018","journal-title":"Am. J. Health Behav."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000526475","article-title":"Remote Treatment Successfully Delivers a Usual Care Weight Loss and Lifestyle Intervention in Adults with Morbid Obesity","volume":"78","author":"Fischer","year":"2022","journal-title":"Ann. Nutr. Metab."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"e42191","DOI":"10.2196\/42191","article-title":"Detailed Versus Simplified Dietary Self-monitoring in a Digital Weight Loss Intervention Among Racial and Ethnic Minority Adults: Fully Remote, Randomized Pilot Study","volume":"6","author":"Patel","year":"2022","journal-title":"JMIR Form. Res."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1111\/dom.16229","article-title":"Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy","volume":"27","author":"Cengiz","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/jamainternmed.2024.3579","article-title":"GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care","volume":"185","author":"Teufel","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/anae.16099","article-title":"Aspiration risk with glucagon-like peptide 1 (GLP-1) agonists","volume":"78","author":"Olesnicky","year":"2023","journal-title":"Anaesthesia"},{"key":"ref_279","first-page":"43","article-title":"Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics","volume":"16","author":"Peleshok","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"Nicze, M., Dec, A., Bor\u00f3wka, M., Krzy\u017cak, D., Bo\u0142dys, A., Bu\u0142dak, \u0141., and Okopie\u0144, B. (2024). Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158202"},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Janket, S.J., Chatanaka, M.K., Sohaei, D., Tamimi, F., Meurman, J.H., and Diamandis, E.P. (2024). Does Incretin Agonism Have Sustainable Efficacy?. Cells, 13.","DOI":"10.3390\/cells13221842"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"bvae197","DOI":"10.1210\/jendso\/bvae197","article-title":"Innovative Glucagon-based Therapies for Obesity","volume":"8","author":"Jemal","year":"2024","journal-title":"J. Endocr. Soc."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/17512433.2024.2409403","article-title":"Amylin analogs for the treatment of obesity without diabetes: Present and future","volume":"17","author":"Panou","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"171203","DOI":"10.1016\/j.peptides.2024.171203","article-title":"Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy","volume":"177","author":"Sun","year":"2024","journal-title":"Peptides"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"156057","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"101880","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol. Metab."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/DMSO.S447582","article-title":"The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity","volume":"17","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/dom.13985","article-title":"Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0\u2009mg: A model-based approach","volume":"22","author":"Papathanasiou","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-018-3525-0","article-title":"Long-Term Outcomes After Bariatric Surgery: A Systematic Review and Meta-analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding","volume":"29","author":"Hindle","year":"2019","journal-title":"Obes. Surg."},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"Duarte-Medrano, G., Nu\u00f1o-L\u00e1mbarri, N., Minutti-Palacios, M., Dominguez-Cherit, G., Dominguez-Franco, A., La Via, L., Patern\u00f2, D.S., and Sorbello, M. (2024). Perioperative Rhabdomyolysis in Obese Individuals Undergoing Bariatric Surgery: Current Status. Healthcare, 12.","DOI":"10.3390\/healthcare12202029"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1210\/jc.2008-1641","article-title":"Bariatric Surgery: Risks and Rewards","volume":"93","author":"Pories","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jamcollsurg.2018.02.013","article-title":"One-Year Mortality after Contemporary Laparoscopic Bariatric Surgery: An Analysis of the Bariatric Outcomes Longitudinal Database","volume":"226","author":"Inaba","year":"2018","journal-title":"J. Am. Coll. Surg."},{"key":"ref_298","first-page":"qxae055","article-title":"Balancing innovation and affordability in anti-obesity medications: The role of an alternative weight-maintenance program","volume":"2","author":"Kim","year":"2024","journal-title":"Health Aff. Sch."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s13300-023-01449-7","article-title":"Should Prediabetes be Treated Pharmacologically?","volume":"14","author":"Davidson","year":"2023","journal-title":"Diabetes Ther."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s13668-024-00551-x","article-title":"Weight Loss Programs: Why Do They Fail? A Multidimensional Approach for Obesity Management","volume":"13","author":"Khattab","year":"2024","journal-title":"Curr. Nutr. Rep."},{"key":"ref_301","doi-asserted-by":"crossref","unstructured":"Zhou, B., Roberts, S.B., Das, S.K., and Naumova, E.N. (2024). Weight Loss Trajectories and Short-Term Prediction in an Online Weight Management Program. Nutrients, 16.","DOI":"10.3390\/nu16081224"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"e70017","DOI":"10.1002\/osp4.70017","article-title":"Four-year follow-up of weight loss maintenance using electronic medical record data: The PROPEL trial","volume":"10","author":"Katzmarzyk","year":"2024","journal-title":"Obes. Sci. Pract."},{"key":"ref_303","doi-asserted-by":"crossref","unstructured":"Borer, K.T. (2021). Why We Eat Too Much, Have an Easier Time Gaining Than Losing Weight, and Expend Too Little Energy: Suggestions for Counteracting or Mitigating These Problems. Nutrients, 13.","DOI":"10.3390\/nu13113812"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1123\/jpah.2012-0250","article-title":"Dietary habits and weight maintenance success in high versus low exercisers in the National Weight Control Registry","volume":"11","author":"Catenacci","year":"2014","journal-title":"J. Phys. Act. Health"},{"key":"ref_305","doi-asserted-by":"crossref","unstructured":"Sforzo, G.A., Gordon, N.F., Peeke, P.M., and Moore, M. (2024). Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss. Am. J. Lifestyle Med., advance online publication.","DOI":"10.1177\/15598276241302273"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/3\/408\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:52:52Z","timestamp":1760028772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/3\/408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":305,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["biom15030408"],"URL":"https:\/\/doi.org\/10.3390\/biom15030408","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}